Zheng O Li

US Patent:

7056663, Jun 6, 2006

Filed:

Mar 23, 2001

Appl. No.:

09/816460

Inventors:

Shanaz H. Dairkee - Orinda CA, US
Zheng Li - Hayward CA, US

Assignee:

California Pacific Medical Center - San Francisco CA

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

Methods of determining the likelihood of the re-occurrence of tumors and of determining the aggressiveness of post-surgical treatment are provided which rely on analysis of a loss of heterogeneity at the particular chromosomal locus 3p24. 3. Loss of expression or hypermethylation of the thyroid hormone receptor β1 gene is also predictive of an increased re-occurrence of tumors.

US Patent:

7723104, May 25, 2010

Filed:

Jan 24, 2007

Appl. No.:

11/626655

Inventors:

Mien-Chie Hung - Houston TX, US
Chi-Ping Day - Houston TX, US
Kun-Ming Rau - Houston TX, US
Xiaoming Xie - Houston TX, US
Zheng Li - Pearland TX, US

Assignee:

Board of Regents, The University Of Texas System - Austin TX

International Classification:

C12N 15/63
C07H 21/04
C12N 15/85

US Classification:

4353201, 536 241, 435325

Abstract:

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.

US Patent:

7816131, Oct 19, 2010

Filed:

Apr 1, 2005

Appl. No.:

11/096622

Inventors:

Mien-Chie Hung - Houston TX, US
Chi-Ping Day - Houston TX, US
Kun-Ming Rau - Niau-Sung Shiang, TW
Xiaoming Xie - Houston TX, US
Zheng Li - Pearland TX, US

Assignee:

Board of Regents, The University of Texas System - Austin TX

International Classification:

C12N 15/36
A61K 48/00

US Classification:

4353201, 424 931, 514 44

Abstract:

The present invention regards cancer-specific control sequences that direct expression of a polynucleotide encoding a therapeutic gene product for treatment of the cancer. Specifically, the invention encompasses breast cancer-, prostate cancer-, and pancreatic cancer-specific control sequences. Two breast cancer-specific sequences utilize specific regions of topoisomerase IIα and transferrin receptor promoters, particularly in combination with an enhancer. The prostate cancer-specific and pancreatic cancer-specific control sequences utilize composites of tissue-specific control sequences, a two-step transcription amplification sequence, and a post-transcriptional control sequence. In more particular embodiments, these polynucleotides are administered in combination with liposomes.

US Patent:

20050130170, Jun 16, 2005

Filed:

Dec 16, 2003

Appl. No.:

10/737082

Inventors:

Jeanne Harvey - Livermore CA, US
Chris Beard - Concord CA, US
Chris Burgess - Westwood MA, US
Allison Gannon - Walnut Creek CA, US
John Lechner - Richmond CA, US
Zheng Li - Hayward CA, US

International Classification:

C12Q001/68

US Classification:

435006000

Abstract:

The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.

US Patent:

20050130172, Jun 16, 2005

Filed:

Jan 27, 2004

Appl. No.:

10/765790

Inventors:

Chris Beard - Concord CA, US
Chris Burgess - Westwood MA, US
Allison Gannon - Walnut Creek CA, US
Jeanne Harvey - Livermore CA, US
John Lechner - Richmond CA, US
Zheng Li - Hayward CA, US

International Classification:

C12Q001/68
G06F019/00
G01N033/48
G01N033/50

US Classification:

435006000, 702020000

Abstract:

The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.

US Patent:

20050214812, Sep 29, 2005

Filed:

Jun 7, 2005

Appl. No.:

11/010980

Inventors:

Zheng Li - Hayward CA, US
Jeanne Harvey - Livermore CA, US

International Classification:

C12Q001/68
C12P019/34

US Classification:

435006000, 435091200

Abstract:

The present invention relates to detecting the relative methylation levels at one or more CpG sites on a nucleic acid molecule, by using the methylation specific primer extension reaction (MSPE). MSPE uses an agent to modify unmethylated cytosine at a CpG site to uracil and subsequently amplify the chemically treated nucleic acids. The MSPE primers distinguishing between unmethylated and methylated CpG sites are provided to conduct MSPE. Relative methylation levels at one or more CpG sites are performed by detecting the signal intensity of labels incorporated into the MSPE reaction products.

US Patent:

20090082214, Mar 26, 2009

Filed:

Dec 21, 2007

Appl. No.:

11/963725

Inventors:

Zhiping Liu - Mountain View CA, US
Zheng Li - Hayward CA, US

Assignee:

Apollo Biotechnology, Inc. - Mountain View CA

International Classification:

C40B 30/04
C40B 40/06
C40B 50/00
C40B 40/12

US Classification:

506 9, 506 16, 506 19, 506 23

Abstract:

This invention relates to conjugate probes and optical detection of analytes. More specifically, this invention relates to conjugate probes which are used to form an array for a biosensor employing optical detection of analytes.

US Patent:

20100136541, Jun 3, 2010

Filed:

Jun 23, 2009

Appl. No.:

12/489502

Inventors:

Chris Beard - Concord CA, US
Chris Burgess - Westwood MA, US
Allison Gannon - Walnut Creek CA, US
Jeanne Harvey - Mountain View CA, US
John F. Lechner - Richmond CA, US
Zheng Li - San Ramon CA, US

Assignee:

Siemens Healthcare Diagnostics Inc. - Tarrytown NY

International Classification:

C12Q 1/68

US Classification:

435 6

Abstract:

The present invention relates to methods for identifying among the genes that are down-regulated in cells or tissues having disease including cancer, the CpG sites within the CpG islands of said genes, wherein the identified CpG sites show great potential for diagnostic utility. In another aspect, the present invention also provides methods of using the selected CpG sites for purposes of diagnosis, prognosis, staging, assessing or monitoring the therapy of or recovery from a disease such as cancer.